The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability (Q33944200)

30 July 2017

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability (English)

1 reference

30 July 2017

0 references

0 references

5

1 reference

30 July 2017

Antonio Scalfari

1

0 references

George C. Ebers

object named as

George C Ebers

7

0 references

author name string

Anneke Neuhaus

2

1 reference

30 July 2017

Alexandra Degenhardt

3

1 reference

30 July 2017

George P Rice

4

1 reference

30 July 2017

Martin Daumer

6

1 reference

30 July 2017

language of work or name

English

0 references

publication date

9 June 2010

1 reference

30 July 2017

1 reference

30 July 2017

133

1 reference

30 July 2017

Pt 7

1 reference

30 July 2017

1914-1929

1 reference

The relation between inflammation and neurodegeneration in multiple sclerosis brains.

30 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

Multiple sclerosis: an immune or neurodegenerative disorder?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

Multiple sclerosis in the Japanese population

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

The clinical course of neuromyelitis optica (Devic's syndrome).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

Defining the clinical course of multiple sclerosis: Results of an international survey

5 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

5 July 2018

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ118

The treatment of chronic progressive multiple sclerosis with cladribine

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

Epidemiology of multiple sclerosis in London and Middlesex County, Ontario, Canada

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island workshop

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892939

Axonal loss in normal-appearing white matter in a patient with acute MS.

5 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ118

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ118

The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ118

The contribution of demyelination to axonal loss in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ118

Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ118

The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ118

Cyclophosphamide and plasma exchange in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ118

Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976-1980.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ118

The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ118

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ118

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ118

The course of multiple sclerosis in 73 cases with computer-designed curves

21 January 2018

1 reference

12 December 2020

Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

A new scale for evaluating disability in multiple sclerosis

1 reference

12 December 2020

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

1 reference

12 December 2020

Relapses and progression of disability in multiple sclerosis

1 reference

12 December 2020

Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg

1 reference

12 December 2020

The natural history of multiple sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.1093/BRAIN/AWQ118

1 reference

30 July 2017

1 reference

30 July 2017

1 reference